Krystal Biotech Price Target Cut to $375.00/Share From $400.00 by RBC Capital

What happened

RBC Capital cut its price target on Krystal Biotech to $375.00 per share from $400.00 while keeping an Outperform rating on the stock, according to ratings actions reported by Benzinga.

Confirmed

Global impact / market context

A lower price target means RBC expects less upside than before, though Outperform still signals it sees the stock beating peers. Investors may treat the cut as a modest trimming of expectations rather than a change in the underlying story.

Analyst inference

Analyst price targets shape how investors frame a stock's potential return. A cut paired with a maintained Outperform rating suggests RBC adjusted its assumptions or valuation rather than turning negative on Krystal Biotech's business prospects.

Analyst inference

What to watch

1. Watch whether other analysts follow RBC in trimming their price targets on Krystal Biotech, which would show whether the revision reflects a broader view. Confirmed
2. RBC could publish updated research explaining what drove the reduction in its price target; watch for details on changed assumptions or valuation inputs. Proposed
3. Track Krystal Biotech's next financial updates for signs that revenue growth or costs are shifting in ways that could justify further target changes. Analyst inference

Evidence

• Original source link unavailable